Skip to main content
Clinical Trials/NCT00076375
NCT00076375CompletedPhase 2

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Two Concentrations of Nanocrystalline Silver Cream (NPI) Applied Twice Daily in Adults With Mild to Moderate Atopic Dermatitis

Nucryst Pharmaceuticals19 sites in 1 country180 target enrollmentStarted: November 1, 2003Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
180
Locations
19

Study Overview

Brief Summary

Nanocrystalline silver (very small particles of silver) is the active ingredient in Acticoat dressings, which have been approved for the treatment of burns and other wounds. Silver has been used for decades as an effective antimicrobial agent. In animal studies, nanocrystalline silver cream (NPI) has also demonstrated anti-inflammatory activity. Thus, nanocrystalline silver cream is being evaluated in the treatment of inflammatory skin conditions such as atopic dermatitis (eczema).

Approximately 180 study subjects with a definitive diagnosis of mild to moderate eczema will be enrolled in this study. Subjects will be randomly assigned to treatment with placebo, 0.5% NPI or 1% NPI for the 6-week treatment period. Assessments of treatment effect and safety will be performed weekly. Upon completion of the study, subjects may be eligible for 12 weeks of open-label treatment with 1% NPI.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Male or female, any race, 18 to 65 years of age.
  • •Females must be post-menopausal, surgically sterile, or if of child-bearing potential, not pregnant (confirmed by test) and using an adequate method of birth control.
  • •Subjects must have eczema that covers a minimum of 5% total body surface area.
  • •Subjects must agree not to use other eczema medications for the 6-week study treatment period.
  • •Subjects must not be enrolled in another investigational drug study.
  • •Subjects must not be allergic to silver or cocoa butter.

Exclusion Criteria

  • Not provided

Investigators

Sponsor Class
Industry

Study Sites (19)

Loading locations...

Similar Trials